Introduction
============

Neuromodulatory devices offer additional treatment options to refractory pharmacologic intervention for the treatment of chronic cluster headaches (CH). Clinical experience suggests vagus nerve stimulation (VNS) may be beneficial; however, inherent risks are associated with surgical implantation. As such, a need for the development of a non-invasive VNS (nVNS) modality exists.

Aim
===

Evaluate the long-term effects of an nVNS device (gammaCore®) in the extension phase of the Prevention and Acute (PREVA) Treatment of Chronic Cluster Headache study.

Methods
=======

This randomized, controlled study consisted of a 2-week run-in phase, followed by a 4-week randomized (1:1; nVNS vs standard of care \[SoC\]) phase, and a 4-week extension phase. During the extension phase, subjects delivered 3 consecutive 90-second stimulations prophylactically twice daily (mandatory, right side only) and optionally at the onset of a CH attack (2 stimulations on headache side, 1 on opposite side) for rescue treatment. Efficacy end points evaluated in the extension phase were mean number of all CH attacks, pain intensity (range: no pain to very severe pain), treatment success rate, and use of rescue medication. Safety was assessed by monitoring the frequency of adverse events.

Results
=======

A total of 97 subjects, across 10 European sites, were randomized to treatment; 90 entered the extension phase. All data has been collected and will be available for presentation at EHMTIC.

Conclusion
==========

Findings from PREVA are expected to provide further evidence of the sustained clinical effects and continued safety of nVNS in the treatment of chronic CH.
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